Cargando…
维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342882/ https://www.ncbi.nlm.nih.gov/pubmed/31495144 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.08.018 |
_version_ | 1783555619146432512 |
---|---|
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7342882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73428822020-07-16 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习 Zhonghua Xue Ye Xue Za Zhi 经验交流 Editorial office of Chinese Journal of Hematology 2019-08 /pmc/articles/PMC7342882/ /pubmed/31495144 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.08.018 Text en 2019年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 经验交流 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习 |
title | 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习 |
title_full | 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习 |
title_fullStr | 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习 |
title_full_unstemmed | 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习 |
title_short | 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习 |
title_sort | 维奈托克联合利妥昔单抗治疗伊布替尼耐药慢性淋巴细胞白血病一例报告并文献复习 |
topic | 经验交流 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342882/ https://www.ncbi.nlm.nih.gov/pubmed/31495144 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.08.018 |
work_keys_str_mv | AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí AT wéinàituōkèliánhélìtuǒxīdānkàngzhìliáoyībùtìnínàiyàomànxìnglínbāxìbāobáixuèbìngyīlìbàogàobìngwénxiànfùxí |